- Home
- AMAL vs GHRS Comparison
AMAL vs GHRS Comparison
Compare AMAL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | GHRS |
|---|---|---|
| Founded | 1923 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 947.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMAL | GHRS |
|---|---|---|
| Price | $41.34 | $22.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $36.00 | ★ $41.38 |
| AVG Volume (30 Days) | 106.7K | ★ 193.2K |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $6.55 | N/A |
| P/E Ratio | $49.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.13 | $10.96 |
| 52 Week High | $44.01 | $24.66 |
Technical Indicators
Market Signals| Indicator | AMAL | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 61.36 |
| Support Level | $36.50 | $12.65 |
| Resistance Level | $42.70 | $22.88 |
| Average True Range (ATR) | 1.09 | 1.49 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 54.98 | 58.59 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.